The abstract is read at the publisher; the summary is JClub's.
Longitudinal cfDNA methylation cancer detection (CD) predicts pathological complete response and disease-free survival in 70 patients with esophageal squamous cell carcinoma, with post-NAT CD-negative linked to HR 0.33.
- Why it matters: Clinicians need noninvasive biomarkers that track treatment response during neoadjuvant immunochemoradiotherapy, since standard assessment may not capture early tumor eradication.
- What they did: In 70 ESCC patients, serial plasma was collected at four time points (NAT, post-NAT, pre-surgery, post-surgery; n = 183) and targeted whole-genome cfDNA methylation sequencing produced CD values, with positivity defined as CD ≥ 0.7.
- The result: CD positivity fell from 74% pre-NAT to 31% post-NAT (p < 0.001), pre-surgery CD positivity was higher in non-pCR vs pCR (33% vs 0%; p = 0.028), and a model using post-NAT CD plus clinical factors reached AUC 0.764 for pCR; post-NAT CD-negative patients had improved DFS (HR = 0.33; p = 0.035), reproduced in an expanded 30-patient cohort.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.